Cargando…

Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models

Detalles Bibliográficos
Autores principales:	Kuo, Chun-Ting, Chen, Chen-Lin, Li, Chih-Chi, Huang, Guan-Syuan, Ma, Wei-Yuan, Hsu, Wei-Fan, Lin, Ching-Hung, Lu, Yen-Shen, Wo, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434874/ https://www.ncbi.nlm.nih.gov/pubmed/32811854 http://dx.doi.org/10.1038/s41598-020-68553-7

Ejemplares similares

Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models
por: Kuo, Chun-Ting, et al.
Publicado: (2019)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
por: Yim, Kein-Leong
Publicado: (2012)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2016)

mTOR inhibitor Everolimus-induced apoptosis in melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

mTOR inhibitor everolimus reduces invasiveness of melanoma cells
por: Ciołczyk-Wierzbicka, Dorota, et al.
Publicado: (2019)

Author Correction: Membrane potential drives the exit from pluripotency and cell fate commitment via calcium and mTOR
por: Sempou, Emily, et al.
Publicado: (2023)

Correction: Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
por: Kiessling, Michael K., et al.
Publicado: (2017)

Experience with the mTOR Inhibitor Everolimus in Pediatric Liver Graft Recipients
por: Wehming, Mathis, et al.
Publicado: (2023)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines
por: Lin, Hugo You-Hsien, et al.
Publicado: (2014)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Author Correction: Elevated FBXL6 expression in hepatocytes activates VRK2-transketolase-ROS-mTOR-mediated immune evasion and liver cancer metastasis in mice
por: Zhang, Jie, et al.
Publicado: (2023)

Author Correction: Filling the gap between topological insulator nanomaterials and triboelectric nanogenerators
por: Li, Mengjiao, et al.
Publicado: (2022)

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus
por: Silic-Benussi, Micol, et al.
Publicado: (2023)

Author Correction: P53 and mTOR signalling determine fitness selection through cell competition during early mouse embryonic development
por: Bowling, Sarah, et al.
Publicado: (2018)

Author Correction: Tanc2-mediated mTOR inhibition balances mTORC1/2 signaling in the developing mouse brain and human neurons
por: Kim, Sun-Gyun, et al.
Publicado: (2022)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

Author Correction: Continuous aerosol monitoring and comparison of aerosol exposure based on smoke dispersion distance and concentrations during oxygenation therapy
por: Wu, Chih‑Chieh, et al.
Publicado: (2023)

Biodegradable Stent with mTOR Inhibitor-Eluting Reduces Progression of Ureteral Stricture
por: Ho, Dong-Ru, et al.
Publicado: (2021)

Author Correction: The highly GABARAP specific rat monoclonal antibody 8H5 visualizes GABARAP in immunofluorescence imaging at endogenous levels
por: Simons, Indra M., et al.
Publicado: (2019)

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
por: Witzig, T E, et al.
Publicado: (2011)

Successful treatment with the mTOR inhibitor everolimus in a patient with Perivascular epithelioid cell tumor
por: Gennatas, Constantine, et al.
Publicado: (2012)

Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells
por: Justin, Saira, et al.
Publicado: (2020)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

[Retracted] Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells
por: Taglieri, Ludovica, et al.
Publicado: (2023)

Author Correction: Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
por: Liao, Chia-Te, et al.
Publicado: (2022)

Author Correction: Antidepressants during and after Menopausal Transition: A Systematic Review and Meta-Analysis
por: Wu, Ching-Kuan, et al.
Publicado: (2022)

Author Correction: A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening
por: Lung, Jrhau, et al.
Publicado: (2021)

Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Incidence and Risk of Treatment-Related Mortality with mTOR Inhibitors Everolimus and Temsirolimus in Cancer Patients: A Meta-Analysis
por: Qi, Wei-Xiang, et al.
Publicado: (2013)

Author Correction: miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR–p-PI3K/AKT-c-JUN
por: Zhao, Mengyang, et al.
Publicado: (2021)

Author Correction: Pharmacological inhibition of mTOR attenuates replicative cell senescence and improves cellular function via regulating the STAT3-PIM1 axis in human cardiac progenitor cells
por: Park, Ji Hye, et al.
Publicado: (2023)

Author Correction: Amyloid modifier SERF1a interacts with polyQ-expanded huntingtin-exon 1 via helical interactions and exacerbates polyQ-induced toxicity
por: Tsai, Tien-Ying, et al.
Publicado: (2023)

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
por: Hirashima, K, et al.
Publicado: (2012)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell Death
por: Baraz, Rana, et al.
Publicado: (2014)

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer
por: Kordes, S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mh23bh45l9crsuj00cnofab2s7